Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY   US02043Q1076

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/09/2014 04/10/2014 04/11/2014 04/14/2014 04/15/2014 Date
65.9(c) 57.92(c) 55.07(c) 53.54(c) 53.22(c) Last
995 234 1 118 732 1 506 307 1 246 061 1 118 267 Volume
+5.49% -12.11% -4.92% -2.78% -0.60% Change
More quotes
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which develops novel therapeutics based on RNA interference. It is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases, including... 
Sector
Biotechnology
Calendar
05/05Earnings Release
Surperformance© rating of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More about the company
Chart ALNYLAM PHARMACEUTICALS, I
Duration : Period :
Alnylam Pharmaceuticals, I Technical Analysis Chart | ALNY | US02043Q1076 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 44,0 M
EBIT 2014 -192 M
Net income 2014 -189 M
Finance 2014 448 M
Yield 2014 -
Sales 2015 42,0 M
EBIT 2015 -151 M
Net income 2015 -158 M
Finance 2015 790 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 74,0x
EV / Sales 2015 69,3x
Capitalization 3 702 M
More Financials
Latest news on ALNYLAM PHARMACEUTICALS, I
6d ago THURSDAY SECTOR LAGGARDS : Biotechnology, Drugs
6d ago ALNYLAM PHARMACEUTICALS : Thursday's ETF Movers: THRK, XBI
6d ago ALNYLAM PHARMACEUTICALS : Receives Positive Opinion for Orphan Drug Designation ..
04/08 Alnylam Gets Positive Opinion for Orphan Drug Designation in the European Uni..
04/07 ALNYLAM PHARMACEUTICALS : McSwiggen Patent Upheld in European Opposition Proceed..
04/07 ALNYLAM PHARMACEUTICALS : McSwiggen Patent Upheld in European Opposition Proceed..
04/07 ALNYLAM PHARMACEUTICALS : to Hold Webcast Presentation at 13th Annual Needham He..
04/02 ALNYLAM PHARMACEUTICALS : Entry into a Material Definitive Agreement (form 8-K)
04/02 ALNYLAM PHARMACEUTICALS : to Webcast Presentation at 13th Annual Needham Healthc..
04/02 ALNYLAM PHARMACEUTICALS : Receives Positive Opinion for Orphan Drug Designation ..
03/26 ALNYLAM PHARMACEUTICALS : to Reveal Data from its RNAi Therapeutic Programs Targ..
03/26 ALNYLAM PHARMACEUTICALS : Genzyme Exercises its Right to Purchase Additional Sha..
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Technical analysis
Income Statement Evolution
Alnylam Pharmaceuticals, I : Income Statement Evolution
More Financials
EPS Revisions
Alnylam Pharmaceuticals, I : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF